

With the patronage of



SIE - Società Italiana di Ematologia

Current Challenges in Hematology 3rd edition

Rome, NH Vittorio Veneto

22 - 23 January 2025

PRESIDENT

Alessandro Isidori

HONORARY PRESIDENTS

Giuseppe Visani

Adolfo de la Fuente Burguera

SCIENTIFIC COMMITTEE

Alessandro Isidori

Antonio Cuneo

Adolfo de la Fuente Burguera

Francesco Passamonti

Alexander Perl

Umberto Vitolo

Eunice Wang

Elena Zamagni

FACULTY

ADES LIONEL
Paris

ALTMAN JESSICA
Chicago (USA)

BRECCIA MASSIMO
Rome

CANDONI ANNA
Modena

CONCONI ANNA RITA
Biella

CUNEO ANTONIO
Ferrara

DAVER NAVAL
Houston (USA)

DE LA FUENTE BURGUERA ADOLFO
Madrid

DI ROCCO ALICE
Rome

DÖHNER KONSTANZE
Ulm

FATTIZZO BRUNO
Milan

FERRARA FELICETTO
Naples

FERRERI ANDRÉS J. M.
Milan

GAIDANO GIANLUCA
Novara

GENTILE MASSIMO
Cosenza

ISIDORI ALESSANDRO
Pesaro

INNOCENTI IDANNA
Rome

JABBOUR ELIAS
Houston (USA)

JONAS BRIAN ANDREW
Sacramento

LADETTO MARCO
Alessandria

LAURENTI LUCA
Rome

LUCIGNANO MARIANO
Salerno

MARTELLI MAURIZIO
Rome

MARTINO MASSIMO
Reggio Calabria

MATEOS MARIA VICTORIA
Salamanca (Spain)

MAURO FRANCESCA ROMANA
Rome

MINA ROBERTO
Turin

MONTORO JULIA
Barcelona (Spain)

MUNIR THALA
Leeds (UK)

MURRU ROBERTA
Cagliari

MUSTO PELLEGRINO
Bari

MUSURACA GERARDO
Meldola (FC)

PAGANO LIVIO
Rome

PALANDRI FRANCESCA
Bologne

PAPAYANNIDIS CRISTINA
Bologne

PASSAMONTI FRANCESCO
Milan

PECCATORI JACOPO
Milan

PERL ALEXANDER
Philadelphia (USA)

RIGACCI LUIGI
Rome

RIVAS MARTA
Buenos Aires (Argentina)

ROSSI ELENA
Rome

SANNA ALESSANDRO
Florence

SICA SIMONA
Rome

SPOROLETTI PAOLO
Perugia

VENDITTI ADRIANO
Rome

VISANI GIUSEPPE
Pesaro

VISENTIN ANDREA
Padua

VITOLO UMBERTO
Candiolo, Turin

VOSO MARIA TERESA
Rome

WANG EUNICE
Buffalo (USA)

ZAMAGNI ELENA
Bologne

22 January 2025

08.50 Congress open
Alessandro Isidori

09.00 SESSION I Current challenges in Lymphomas

Chairmen: Maurizio Martelli, Umberto Vitolo

09.00 Perspectives in mantle cell lymphoma
Marco Ladetto

09.20 Perspectives in marginal zone lymphoma
Anna Rita Conconi

09.40 CAR-T in DLBCL
Alice Di Rocco

10.00 Therapeutic options in patients with relapsed/refractory DLBC not eligible to CAR-T
Gerardo Musuraca

10.20 Current challenges in advanced-stage Hodgkin disease
Luigi Rigacci

10.40 Talk-show: Bispecific antibodies for relapsed/refractory B cell lymphomas: a new gold standard?
Maurizio Martelli, Umberto Vitolo,
Marco Ladetto, Gerardo Musuraca

11.10 Coffee break

11.30 SESSION II Multiple Myeloma

Chairmen: Maria Victoria Mateos, Elena Zamagni

11.30 How I diagnose and treat high risk MM
Roberto Mina

11.50 Bispecific antibodies: how to choose them and how to manage them
Maria Victoria Mateos

12.10 CAR-T: patient's selection and management
Elena Zamagni

12.30 Bridging the gap: how to integrate therapeutic options for intermediate-fit patients at relapse
Pellegrino Musto

12.50 Talk-show: Bispecific antibodies for multiple myeloma: alternative or complementary to CAR-T? How to sequence them?
Maria Victoria Mateos, Elena Zamagni, Roberto Mina

13.30-14.15 Lunch Symposium (NO ECM)

With the contribution of BEIGENE - Mascagni Room

"SETTING NEW STANDARD IN CLL: ZANUBRUTINIB AS A BALANCE BETWEEN EFFICACY AND SAFETY"

Chairmen: Luca Laurenti, Francesca Romana Mauro

13.30 Welcome and introduction
Luca Laurenti

13.45 Clinical experiences with Zanubrutinib in CLL:
- First line treatment
Idanna Innocenti
- Treatment of R/R patients
Mariano Lucignano

14.00 Conclusions and take-home messages
Francesca Romana Mauro

14.15-15.00 Symposium (NO ECM)

With the contribution of ASTRAZENECA
Mascagni Room

"THE TREATMENT CHOICE IN 1L CHRONIC LYMPHOCYTIC LEUKEMIA: "ONE SIZE FITS ALL"?"

Chair: Alessandro Isidori

14.15 The efficacy and safety of Acalabrutinib: from clinical trials to RWE
Alessandro Sanna

14.30 The right treatment for the right patient: Biology vs Age & Fitness
Roberta Murru

14.45 Panel discussion
Roberta Murru, Alessandro Sanna

15.00-15.45 Symposium (NO ECM)

With the contribution of JANSSEN CILAG
Mascagni Room

INNOVATION IN HEMATOLOGY: PROMISING THERAPIES IN MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: Alessandro Isidori

15.00 From Frontline to Relapse: The Journey through MM
Elena Zamagni

15.20 From Frontline to Relapse: The Journey through CLL
Paolo Sportoletti

15.45-16.15 Symposium (NO ECM)

With the contribution of ABBVIE - Parallel Room

HOW TO OVERCOME THE CURRENT CHALLENGES IN DLCLBL AND CLL

15.45 DLBCL
Chair: Andrés J. M. Ferreri
Eporitamab deep and durable responses: 3-year update
Alice Di Rocco
15.55 Discussione e Q&A

16.00 CLL
Chair: Massimo Gentile
V-X: venetoclax as the backbone therapy in CLL
Andrea Visentin
16.10 Discussione e Q&A

16.15 - 16.30

Sponsored Lecture (NO ECM)

With the contribution of ELI LILLY - Mascagni Room

16.15 Pirtobrutinib ed il nuovo algoritmo di trattamento del linfoma mantellare recidivante o refrattario (R/R)

Gerardo Musuraca

16.30 Open coffee break

16.40 Talk show - Is all good enough in PNH?

Bruno Fattizzo, Simona Sica

17.10 SESSION III Chronic lymphocytic leukemia

Chairmen: Francesca Romana Mauro, Antonio Cuneo

17.10 How biology influences treatment in CLL

Gianluca Gaidano

17.30 CLL therapy guided by measurable residual disease

Tahla Munir

17.50 Perspectives in refractory/resistant CLL

Paolo Sportoletti

18.10 Talk-Show: Fixed duration versus continuous therapy in 1L CLL: the final frontier

Antonio Cuneo, Gianluca Gaidano,
Francesca Romana Mauro, Tahla Munir,
Paolo Sportoletti

18.40 SESSION IV Myeloproliferative neoplasms

Chairmen: Francesco Passamonti, Massimo Breccia

18.40 How I treat polycythemia vera

Francesco Passamonti

19.00 Rusfertide in polycythemia vera: data from clinical trials

Alessandro Isidori

19.15 New treatment options for CML patients in second or subsequent lines of therapy

Massimo Breccia

19.35 Current management of patients with myelofibrosis

Francesca Palandri

19.55 Discussion

20.30 Day-1 closing

23 January 2025

09.00 Lecture: Challenges in treatment of immune thrombocytopenia (ITP)
Elena Rossi

09.20 SESSION V Myelodysplastic syndromes

Chairmen: Maria Teresa Voso, Eunice Wang

09.20 Germline predisposition: clinical and ethical relevance
Julia Montoro

09.40 Perspectives and innovations in low-risk MDS
Lionel Ades

10.00 Perspectives and innovations in high-risk MDS
Eunice Wang

10.20 Discussion

10.30 SESSION VI Acute Myeloid Leukemia (I)

Chairmen: Konstanze Döhner, Giuseppe Visani

10.30 How molecular information guide treatment decision-making in AML patients
Konstanze Döhner

10.50 Treatment of high-risk AML
Eunice Wang

11.10 Optimal approaches to frontline FLT3 ITD AML
Alexander Perl

11.30 Discussion

11.40 Coffee break

12.00 SESSION VII Acute Myeloid Leukemia (II)

Chairmen: Alessandro Isidori, Alexander Perl

12.00 Optimizing outcomes and practical management of patients treated with HMA-venetoclax based regimen
Brian Andrew Jonas

12.20 Menin inhibitors in AML
Jessica Altman

12.40 Acute promyelocytic leukemia in 2025
Maria Teresa Voso

13.00 Discussion

13.20-14.20

Lunch Symposium (NO ECM)

With the contribution of DAIICHI SANKYO
Mascagni Room

FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
Chair: Adriano Venditti

13.20 Welcome and introduction
Adriano Venditti

13:25 Is FLT3-ITD mutated AML really an intermediate-risk disease?
Maria Teresa Voso

13:40 Maintenance therapy in AML-FLT3-ITD + pts: what is the future?
Felicetto Ferrara

13:55 Talk-Show: how optimize treatment with FLT3i: is it time to define a sequencing strategy?
Introduction by Alessandro Isidori

14.20

Sponsored Lecture (NO ECM)

With the contribution of ABBVIE - Mascagni Room

14.20 AML

Chair: Anna Candoni
Improving AML patients life with VEN+AZA
Alessandro Isidori

14.35 Discussione e Q&A

14.40 Talk-Show Conditioning regimens and early complications in allogeneic stem cell transplantation
Massimo Martino, Jacopo Peccatori

15.10 SESSION VII

Breaking news from MD Anderson

Chairmen: Adolfo de la Fuente, Alessandro Isidori

15.10 Breaking news in ALL
Elias Jabbour

15:30 Breaking news in AML
Naval Daver

15:50 Discussion

16.00 Lecture - Current treatment of adult patients with acute lymphoblastic leukemia
Cristina Papayannidis

16.20 SESSION VIII **Acute Myeloid Leukemia (III)**

Chairmen: Felicetto Ferrara, Marta Rivas

16.20 Maintenance in AML: a true alternative to allo-SCT for some patients?

Adolfo de la Fuente Burguera

16.40 Treatment of elderly patients with IDH1 +ve AML

Adriano Venditti

17.00 Alternative treatments for unfit patients with AML

Alessandro Isidori

17.20 Diagnosis and treatment of BPDCN

Livio Pagano

17.40 Discussion

17.50 Closing remarks – see you in 2026

Alessandro Isidori

CME INFO & REGISTRATION

Event n. 2007-434837

Objective n. 3

15 CME Credits for: Hematologists and Biologists

Free registration: www.proeventi.it

pin : current2025 (DEEP ECM APP)

ITALIAN ECM ACCREDITATION

Each participant, to obtain ECM credits, must attend at least 90% of the scientific work and complete the online ECM questionnaire with at least 75% of correct answers.

Attendance will be registered via QR code reader.

VENUE

NH VITTORIO VENETO, Rome

[Corso d'Italia, 1, 00198 Roma RM](#)

CONFERENCE CENTER -1 FLOOR

ECM AREA: TIZIANO + BOTTICELLI

LUNCH ROOM: MASCAGNI

EXPO AREA: VERDI

SYMPOSIA ROOM: PUCCINI

LANGUAGE

Italian speakers will present their works in Italian.

Foreign speakers will present their works in English.

Foreigners guests will receive the headset with simultaneous translation.

EDUCATIONAL GRANT

The organization offers travel grants for those interested in participating.

You can send your application to info@proeventi.it

The scientific committee will select the first 50 relevant applications.

SCIENTIFIC SECRETARIAT

Alessandro Isidori

Federica Loscocco

ORGANIZING SECRETARIAT



www.proeventi.it

info@proeventi.it

With the unrestricted educational grant of



PLATINUM SPONSOR

abbvie

GOLD SPONSOR

AstraZeneca 

 BeiGene


Daiichi-Sankyo


Johnson & Johnson


Lilly

SILVER SPONSOR

AMGEN

 Incyte

 Jazz Pharmaceuticals

 Otsuka
Otsuka Pharmaceutical Italy S.r.l.

sanofi

SERVIER*
moved by you

BRONZE SPONSOR

 Bristol Myers Squibb

medac
PHARMA

 KURA
ONCOLOGY

 MENARINI
group

 NOVARTIS

 sobi
rare strength

 Takeda

CONTRIBUTORS

ALEXION[®]
AstraZeneca Rare Disease

 GILEAD

 Protagonist
Therapeutics

 Roche